Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 73384-59-5] Ceftriaxone

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0712
Brand:	MCE
CAS:	73384-59-5

Overview

MDL	-
Molecular Weight	554.58
Molecular Formula	C18H18N8O7S3
SMILES	O=C(C(N12)=C(CSC(N(C)NC3=O)=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

[1]Nat Commun. 2022 Mar 2;13(1):1116.
[2]Emerg Microbes Infect. 2024 Dec;13(1):2321981.
[3]EBioMedicine. 2022 Apr;78:103943.
[4]Chemosphere. 2023 Oct 3:344:140353.

Summary

Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic , which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC ₅₀ value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B . Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis ^[1] ^[2] ^[3] ^[4] ^[5] ^[6] ^[7] .

IC50 & Target

β-lactam

In Vitro

Ceftriaxone (100 μM, 24 h) protects MPP ⁺ treated astrocytes by inhibiting the NF-κB/JNK/c-Jun signaling pathway [3].
Ceftriaxone (500 μM, 24-48 h) effectively inhibits unanchored cell growth in A549, H520 and H1650 lung cancer cells by inhibiting Aurora B ^[4] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ceftriaxone Related Antibodies

Aurora B Antibody
Phospho-GSK3 beta (Ser9) Antibody
Phospho-GSK3 beta(Ser 9) Antibody
GSK3 beta Antibody (YA397)
Aurora A Antibody (YA827)

Cell Viability Assay ^[3]

Cell Line:	Astrocyte
Concentration:	100 μM
Incubation Time:	24 h
Result:	Improved cell viability and increased glutamate uptake after MPP ⁺ expose.

Western Blot Analysis ^[3]

Cell Line:	Astrocyte
Concentration:	100 μM
Incubation Time:	24 h
Result:	Enhanced GLT-1 and GFAP expression. Decreased the expression of p-p50、p-IKKα、p-Relb. Decreased the number of TUNEL-positive cells.

In Vivo

Ceftriaxone (200 mg/kg Intraperitoneal injection for 6 weeks) improves functional markers and oxidative stress and inflammation parameters in a rat model of D-galactose (DGL) -induced liver and kidney injury ^[5] .
Ceftriaxone (200, 400 mg/kg, Intraperitoneal injection) has a protective effect on convulsion induced by Pentylenetetrazol (PTZ) and PTZ-related oxidative damage in rats ^[6] .
Ceftriaxone (100, 200 mg/kg, Intraperitoneal injection) reduces mechanical dysodynia and hyperalgesia by activating GLT-1 in Streptozocin ( HY-13753 )-induced diabetic rat models ^[7] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DGL-induced rat model ^[5]
Dosage:	200 mg/kg
Administration:	i.p.
Result:	Reduced the BUN、Cr 、AST and ALT levels. Attenuated the MDA levels and enhanced GPx and CAT activities. Reduced the levels of IL-1β and TNF-α mRNA.

Animal Model:	PTZ-induced rat model ^[6]
Dosage:	200, 400 mg/kg
Administration:	i.p. 60 min before to PTZ (70 mg/kg)
Result:	Both of the two ceftriaxone groups had lower spike percentages than the saline group. Significantly lower MDA levels and higher SOD activity in 200 and 400 mg/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03449940	Ministry of Health, Jamaica\|University Hospital of the West Indies	Erectile Dysfunction	January 2015	Not Applicable
NCT04141787	Vancouver Island Health Authority	Staphylococcal Infections\|Osteomyelitis\|CNS Infection\|Septic Arthritis\|Diabetic Foot Infection\|Vertebral Osteomyelitis\|Abscess\|Coagulase Negative Staphylococcal Infection	July 11, 2019	Phase 4
NCT00493220	Baxter Healthcare Corporation\|Halozyme Therapeutics	Healthy	June 2007	Phase 1
NCT00512616	National Institute of Mental Health (NIMH)\|National Institutes of Health Clinical Center (CC)	Bipolar Disorder	August 1, 2007	Phase 2
NCT02742948	Cairo University	Endometritis	April 2016	Phase 2
NCT01988428	Amsterdam UMC, location VUmc\|Stichting Nuts Ohra\|Nederlandse Internisten Vereniging ( Dutch Association of Internists)	Sepsis\|Severe Sepsis\|Septic Shock	June 2014	Not Applicable
NCT02328469	University Medical Centre Ljubljana\|Slovenian Research Agency\|University of Ljubljana School of Medicine, Slovenia\|Harvard University	Aseptic Meningitis	June 2014
NCT01723150	National University Hospital, Singapore\|Tan Tock Seng Hospital\|Singapore General Hospital	Liver Abscess, Pyogenic	November 5, 2013	Phase 4
NCT02567825	Alejandro Hoberman\|George Washington University\|National Institute on Deafness and Other Communication Disorders (NIDCD)\|University of Pittsburgh	Acute Otitis Media	November 2015	Not Applicable
NCT00449800	Association Pour La Promotion A Tours De La Reanimation Medicale	Sepsis\|Severe Sepsis\|Septic Shock	July 2006	Phase 4
NCT01421693	Oxford University Clinical Research Unit, Vietnam\|University of Oxford\|Patan Academy of Health Sciences, Nepal\|Patan Hospital, Nepal\|Civil Hospital, Nepal	Enteric Fever\|Typhoid Fever	September 2011	Phase 4
NCT00566111	Yale University\|Stanley Medical Research Institute	Bipolar Depression	September 2007	Not Applicable
NCT00004216	Vion Pharmaceuticals\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	August 1999	Phase 1
NCT04839653	MEDSI Clinical Hospital 1, ICU	Pneumonia, Ventilator-Associated\|Pneumonia\|Bloodstream Infection\|Sepsis\|Respiratory Distress Syndrome\|Respiratory Tract Infections\|Critical Illness	May 1, 2021	Not Applicable
NCT03061604	Theodor Bilharz Research Institute\|Université Libre de Bruxelles	Variceal Hemorrhage	November 2014	Not Applicable
NCT00326287	Basilea Pharmaceutica	Pneumonia	June 2006	Phase 3
NCT05051163	Makerere University	HIV-1-infection\|Malnutrition, Child	June 14, 2021	Phase 2\|Phase 3
NCT00621504	Forest Laboratories	Bacterial Pneumonia	January 2008	Phase 3
NCT05079620	UConn Health	Aspiration\|Aspiration Pneumonia	November 30, 2021	Phase 4
NCT03959527	Global Antibiotics Research and Development Partnership	Gonorrhea	November 6, 2019	Phase 3
NCT04870138	National Institute of Allergy and Infectious Diseases (NIAID)	Gonococcal Infection	March 10, 2013	Phase 1
NCT00035347	Pfizer	Community-Acquired Pneumonia (CAP)	January 2001	Phase 4
NCT01163994	University Medical Centre Ljubljana	Multiple Erythema Migrans	June 2010	Not Applicable
NCT01265173	Korea University	SBP\|Liver Cirrhosis	April 2007	Phase 4
NCT00942006	University Medical Centre Ljubljana	Suspected Early Lyme Neuroborreliosis	July 2009	Not Applicable
NCT03794765	Postgraduate Institute of Medical Education and Research	Ulcerative Colitis\|Inflammatory Bowel Diseases\|Acute Severe Colitis	April 1, 2019	Phase 2
NCT01390623	University Hospital, Clermont-Ferrand	Acute Uncomplicated Pyelonephritis	July 2011	Phase 4
NCT01669980	Forest Laboratories	Infections\|Pneumonia	October 2012	Phase 4
NCT00001101	National Institute of Allergy and Infectious Diseases (NIAID)	Lyme Disease		Phase 3
NCT03179384	Centre Hospitalier Universitaire de Nice	Pyelonephritis Acute	June 26, 2017	Phase 4
NCT00230971	Wyeth is now a wholly owned subsidiary of Pfizer	Appendicitis\|Cholecystitis\|Diverticulitis\|Intra-Abdominal Abscess\|Intra-Abdominal Infection\|Peritonitis	October 2005	Phase 4
NCT00481702	Merck Sharp & Dohme LLC	Intra-abdominal Infection	December 2001	Phase 3
NCT00000648	National Institute of Allergy and Infectious Diseases (NIAID)\|Hoffmann-La Roche	HIV Infections\|Neurosyphilis		Not Applicable
NCT02142751	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\|Spanish Network for Research in Infectious Diseases	Infection Due to ESBL Escherichia Coli	July 2014	Phase 3
NCT00111644	Hoffmann-La Roche	Pneumonia, Bacterial	March 2005	Phase 2
NCT05375240	Tianjin Medical University General Hospital	Stroke\|Cerebrovascular Disorders\|Ischemic Stroke\|Brain Diseases\|Central Nervous System Diseases\|Nervous System Diseases\|Cardiovascular Diseases\|Propranolol\|Beta Blocker\|Molecular Mechanisms of Pharmacological Action\|Immunologic Factors\|Physiological Effects of Drugs	June 2022	Phase 2
NCT05149287	Austin V Stone\|University of Kentucky	Meniscus Tear\|Meniscus Lesion\|Cartilage Injury	December 28, 2021	Phase 2
NCT04771884	Shandong University\|Children´s Hospital of Chongqing Medical University	Bacterial Meningitis\|Augmented Renal Clearance	October 1, 2020
NCT03560232	Mercy Health Ohio	Open Fracture\|Post-Op Wound Infection	July 9, 2018	Phase 4
NCT01150747	Harold Wiesenfeld\|National Institute of Allergy and Infectious Diseases (NIAID)\|University of Pittsburgh	Chlamydia	January 2011
NCT00431678	Bayer	Pneumonia	January 2004	Phase 3
NCT00037479	National Institute of Neurological Disorders and Stroke (NINDS)	Lyme Disease\|Lyme Neuroborreliosis	December 1999	Phase 2
NCT00769171	Bayer	Infection, Intra-abdominal	October 2005	Phase 3
NCT04041791	University of Oxford\|University of Nairobi\|London School of Hygiene and Tropical Medicine\|National Institute for Health Research, United Kingdom\|Department for International Development, United Kingdom\|Medical Research Council\|Wellcome Trust\|Kenya Ministry of Health	Pneumonia	August 19, 2019	Phase 3
NCT02735707	UMC Utrecht\|Australian and New Zealand Intensive Care Research Centre\|Medical Research Institute of New Zealand\|Unity Health\|Berry Consultants\|Global Coalition for Adaptive Research\|University of Pittsburgh Medical Center\|Intensive Care National Audit & Research Centre\|St. Marianna University School of Medicine\|National Intensive Care Surveillance MORU	Community-acquired Pneumonia, Influenza, COVID-19	April 11, 2016	Phase 3
NCT01247909	Kamuzu University of Health Sciences	Infant Bacterial Meningitis	April 2010	Phase 4
NCT00910533	University Medical Centre Ljubljana	Nervous System Lyme Borreliosis	January 1, 2009	Not Applicable
NCT00914888	Wyeth is now a wholly owned subsidiary of Pfizer	Community Acquired Bacterial Pneumonia\|Complicated Intra-Abdominal Infection	January 2011	Phase 3
NCT05398081	Dr. Promise Tamunoipiriala Jaja\|University College Hospital, Ibadan	Surgical Site Infection\|Antibiotics Prophylaxis	December 1, 2021	Phase 2
NCT02015637	Melinta Therapeutics, Inc.	Gonorrhea	January 23, 2014	Phase 3
NCT01278017	Chang Gung Memorial Hospital	Diarrhea	August 2010	Phase 4
NCT03840811	National Institute of Allergy and Infectious Diseases (NIAID)	Gonococcal Infection	April 23, 2017	Phase 1
NCT04066621	Xiangbei Welman Pharmaceutical Co., Ltd	Respiratory Tract Infections\|Urinary Tract Infections in Children	April 28, 2015	Phase 4
NCT02257918	National Institute of Allergy and Infectious Diseases (NIAID)	Gonorrhoea	November 25, 2014	Phase 2
NCT01635530	Turku University Hospital	Lyme Neuroborreliosis	August 2012	Phase 4
NCT05216744	Haiphong University of Medicine and Pharmacy	Neisseria Gonorrhoeae Infection\|Chlamydia Trachomatis Infection	July 15, 2021	Phase 2
NCT02561442	scPharmaceuticals, Inc.	Pharmacokinetics in Healthy Adults	October 2015	Phase 2\|Phase 3
NCT01659866	Northwestern University	Infection	August 2012	Phase 4
NCT03012360	University Hospital, Lille\|Ministry of Health, France	Mechanical Ventilation Complication\|Critical Illness	February 8, 2018	Phase 4
NCT01371838	Pfizer\|Forest Laboratories	Community-Acquired Bacterial Pneumonia\|Lung Infection of Individual Not Recently Hospitalized	December 2011	Phase 3
NCT01757236	University Hospital, Tours\|Pfizer\|International Clinical Trials Association	Hip Prosthetic Joint Infection	October 2012	Phase 2
NCT00509106	Forest Laboratories	Bacterial Pneumonia	July 2007	Phase 3
NCT00895089	Kaohsiung Veterans General Hospital.\|Bayer	Liver Abscess	May 2009	Phase 4
NCT04218695	Beth Israel Deaconess Medical Center\|American Association for the Study of Liver Diseases Foundation	Cirrhosis, Liver	August 24, 2020	Phase 4
NCT01014013	Merck Sharp & Dohme LLC	Urinary Tract Infection	April 2008	Phase 3
NCT02210325	Melinta Therapeutics, Inc.\|National Institute of Allergy and Infectious Diseases (NIAID)	Uncomplicated Urogenital Gonorrhea	August 2014	Phase 3
NCT05943223	McMaster Children´s Hospital	Appendicitis Perforated	January 2024	Phase 2
NCT02424461	Assistance Publique - Hôpitaux de Paris	Acute Male Urinary Tract Infection	February 2015	Phase 3
NCT02473263	Assistance Publique - Hôpitaux de Paris	Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit	May 9, 2016	Phase 3
NCT02098486	Kangbuk Samsung Hospital	Cholangitis	March 2014	Phase 2
NCT05654896	Nadeem Iqbal\|Ahmad Zia\|Muhammad Junaid Tahir\|Pakistan Kidney and Liver Institute and Research Center	Antibiotic Prophylaxis	November 26, 2022	Phase 3
NCT00349622	Massachusetts General Hospital\|National Institute of Neurological Disorders and Stroke (NINDS)	Amyotrophic Lateral Sclerosis\|ALS	July 2006	Phase 3
NCT05294588	University of North Carolina, Chapel Hill\|National Institute of Allergy and Infectious Diseases (NIAID)	Gonorrhea Male	April 18, 2022	Phase 2
NCT00451386	Merck Sharp & Dohme LLC	Urinary Tract Infections\|Bacterial Pneumonia\|Soft Tissue Infections	January 2002	Phase 2
NCT03681431	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Infectious Endocarditis	April 23, 2018	Phase 2
NCT03895567	University of Oxford\|Biopharma (Orofino Pharmaceuticals Group)	Healthy	June 2024	Phase 1
NCT01473836	Pfizer	Intra-abdominal Infections	November 2011	Phase 3
NCT05971550	Assistance Publique - Hôpitaux de Paris	Neisseria Gonorrhoeae Infection\|Asymptomatic Pharyngeal Carriage	September 2023	Phase 3
NCT02659033	Assistance Publique - Hôpitaux de Paris	Emergence of Bacterial Resistance to Antibiotics	March 2016	Phase 3
NCT04975945	The Grant Medical College & Sir J.J. Group of Hospitals	Surgical Wound Infection\|Surgical Site Infection	August 2021	Phase 4
NCT00161330	University of Padova\|Regione Veneto\|IL Sogno di Stefano	Urinary Tract Infections	June 2000	Phase 3
NCT02334124	Murdoch Childrens Research Institute	Cellulitis	January 2015	Not Applicable
NCT04202068	Xiangbei Welman Pharmaceutical Co., Ltd	Gonorrhea	July 3, 2015	Phase 4
NCT00358202	CPL Associates\|Elan Pharmaceuticals	Pneumonia	March 2002	Phase 4
NCT00797108	Pfizer	Pneumonia, Bacterial	January 2009	Phase 2
NCT05980871	National Taiwan University Hospital	Early Syphilis	March 10, 2023	Phase 4
NCT00000938	National Institute of Allergy and Infectious Diseases (NIAID)	Lyme Disease		Phase 3
NCT02746276	University of Oxford\|KEMRI-Wellcome Trust Collaborative Research Program\|Centre for Research in Therapeutic Sciences, Strathmore University, Nairobi Kenya\|University College, London\|Centre for Microbiology Research, Kenya Medical Research Institute\|Centre for Clinical Research, Kenya Medical Research Institute	Malnutrition	April 1, 2016	Phase 2
NCT05470517	Johns Hopkins All Children´s Hospital	Complicated Appendicitis\|Acute Appendicitis	January 5, 2023	Phase 2
NCT00429975	Hospital Mutua de Terrassa\|Fondo de Investigacion Sanitaria	Pneumonia, Pneumococcal	August 2004	Phase 4
NCT00374959	Hospital Universitario Principe de Asturias\|Hoffmann-La Roche	Pneumonia	October 2000	Phase 4
NCT03087656	University of Southern California	Cholangitis	March 29, 2017	Phase 4
NCT03068741	Dr. Damon Scales\|Canadian Institutes of Health Research (CIHR)\|Sunnybrook Research Institute\|Sunnybrook Health Sciences Centre	Severe Sepsis or Septic Shock	March 23, 2020	Phase 4
NCT02177994	Ain Shams Maternity Hospital	Infection of Cesarian Section Wound Following Delivery	September 2013	Phase 3
NCT00591318	Research Foundation for Mental Hygiene, Inc.\|National Alliance for Research on Schizophrenia and Depression\|New York State Psychiatric Institute	Psychosis\|Schizophrenia\|Schizoaffective Disorder	October 10, 2007	Phase 1\|Phase 2
NCT00138801	Sorlandet Hospital HF	Lyme Neuroborreliosis	March 2004	Phase 3
NCT03133637	University of Rochester	Jaundice and Sepsis in Neonates	March 2016
NCT02996656	Université de Montréal\|Stryker Trauma GmbH\|Hopital du Sacre-Coeur de Montreal	Propionibacterium Infection	December 2016	Not Applicable
NCT01530763	Forest Laboratories\|AstraZeneca	Infections\|Community Acquired Pneumonia	September 2012	Phase 2\|Phase 3
NCT01745679	Nantes University Hospital	Meningitis\|Neurological Infections	December 2012	Phase 4
NCT03294395	Public Health Service of Amsterdam\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Gonorrhea	September 18, 2017	Phase 3
NCT01254344	Merck Sharp & Dohme LLC	Infection\|Surgical Site Infection	December 2010	Phase 3
NCT02384200	University of California, San Diego\|Mayo Clinic\|University of British Columbia\|The Cleveland Clinic\|Duke University\|Ohio State University\|Dartmouth-Hitchcock Medical Center\|Vanderbilt University\|New York University	Nephrolithiasis\|Urinary Tract Infections	March 2015	Phase 4
NCT01160640	Harold Wiesenfeld\|National Institute of Allergy and Infectious Diseases (NIAID)\|University of Pittsburgh	Pelvic Inflammatory Disease	November 2010	Phase 2
NCT00002052	University of Southern California\|NIH AIDS Clinical Trials Information Service	HIV Infections\|Salmonella Infections		Not Applicable
NCT01645735	Forest Laboratories\|AstraZeneca	Infections	October 2012	Phase 4
NCT03174236	University of Oxford\|University College, London\|London School of Hygiene and Tropical Medicine\|Swansea Trials Unit\|Kenya Medical Research Institute\|KEMRI-Wellcome Trust Collaborative Research Program	Malnutrition Severe\|Antibiotic Resistance\|Antibiotic Toxicity	September 4, 2017	Phase 3
NCT00372541	Makerere University	Pneumonia	September 2006	Phase 3
NCT02443285	Tanta University	Primary Bacterial Peritonitis	January 2015	Phase 3
NCT02473640	Theriva Biologics, Inc.	Healthy Volunteers With Ileostomy	June 2015	Phase 1\|Phase 2
NCT03903783	Groupe Hospitalier Paris Saint Joseph	Infection, Bacterial	April 30, 2019	Not Applicable
NCT00195351	Wyeth is now a wholly owned subsidiary of Pfizer	Appendicitis\|Cholecystitis\|Cross Infection\|Diverticulitis\|Peritonitis	September 2005	Phase 4
NCT04010539	GlaxoSmithKline	Gonorrhea	October 21, 2019	Phase 3
NCT00157898	Merck Sharp & Dohme LLC	Complicated Intra-abdominal Infection	January 2004	Phase 4
NCT03413384	BrainX Corporation\|Virginia Contract Research Organization Co., Ltd.	Parkinson´s Disease Dementia	February 15, 2019	Phase 2
NCT02224040	Sheba Medical Center	Typhoid Fever	August 2013	Phase 4
NCT01602874	Pfizer	Community Acquired Bacterial Pneumonia\|Complicated Intra-Abdominal Infection	January 2011	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 31.25 mg/mL ( 56.35 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8032 mL	9.0158 mL	18.0317 mL
5 mM	0.3606 mL	1.8032 mL	3.6063 mL
10 mM	0.1803 mL	0.9016 mL	1.8032 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% Saline

Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution

* All of the co-solvents are available by MedChemExpress (MCE).

References

[1] Nahata MC, et al. Ceftriaxone: a third-generation cephalosporin. Drug Intell Clin Pharm. 1985 Dec;19(12):900-6.
[2] Nassar H, et al. Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors. RSC Adv. 2023 Apr 11;13(17):11278-11290.
[3] Zhang Y, et al. Ceftriaxone Protects Astrocytes from MPP(+) via Suppression of NF-κB/JNK/c-Jun Signaling. Mol Neurobiol. 2015 Aug;52(1):78-92.
[4] Li X, et al. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. Carcinogenesis. 2012 Dec;33(12):2548-57.
[5] Hakimizadeh E, et al. Ceftriaxone improves hepatorenal damages in mice subjected to D-galactose-induced aging. Life Sci. 2020 Oct 1;258:118119.
[6] Uyanikgil Y, et al. Positive effects of ceftriaxone on pentylenetetrazol-induced convulsion model in rats. Int J Neurosci. 2016;126(1):70-5.
[7] Gunduz O, et al. Anti-allodynic and anti-hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. Neurosci Lett. 2011 Mar 10;491(1):23-5.

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart